Phuturdex › Diseases › Esophageal neoplasm
Drugs in development · updated 30 October 2026
Esophageal neoplasm: drugs in development
As of 30 October 2026 there are 180 active clinical trials (recruiting or ongoing, phases I–III) on 191 drugs for esophageal neoplasm. 121 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 121 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PaclitaxelTaxol, Paxlitaxel | III | 22 | NCT05357846 |
| CarboplatinCarboplatine, Paraplatin | III | 20 | NCT07306663 |
| CisplatinCis Platinum, Cisplatine | III | 20 | NCT05152147 |
| OxaliplatinOxaliplatine, Oxaliplain | III | 17 | NCT05152147 |
| NivolumabOpdivo, ONO-4538 | III | 16 | NCT07431281 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 12 | NCT05152147 |
| LeucovorinFolinic acid, l-leucovorin | III | 11 | NCT07431281 |
| CapecitabineXeloda, Capectitabine Tablets | III | 10 | NCT05152147 |
| TislelizumabTisleizumab, Tiselizumab | III | 9 | NCT06914011 |
| TrastuzumabHerceptin, tratuzumab | III | 8 | NCT05152147 |
| IrinotecanOnivyde, CPT-11 | III | 5 | NCT04415853 |
| ToripalimabJS001, Teripalimab | III | 3 | NCT07177794 |
| PertuzumabPerjeta, Poherdy® | III | 2 | NCT05188313 |
| ZanidatamabZiihera® | III | 2 | NCT05152147 |
| SevofluraneUltane® | III | 1 | NCT04513808 |
Sorted by most advanced phase and number of active trials. Showing 15 of 70 drugs.
All 191 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Esophageal squamous cell carcinoma 115 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Non-small-cell lung carcinoma 726 drugs
- Uterine cervix neoplasm 224 drugs
- Metastasis 493 drugs
- Triple-negative breast neoplasm 334 drugs
- Colorectal neoplasm 534 drugs
- Endometrial neoplasm 298 drugs
- Esophagus adenocarcinoma 82 drugs
- Stomach neoplasm 340 drugs
- Melanoma 352 drugs
- Lung small cell carcinoma 197 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Gastrointestinal disease 22 drugs
- Esophageal disease 5 drugs
- Digestive system neoplasm 37 drugs
- Gastrointestinal neoplasm 80 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D004938 “Esophageal Neoplasms”.